93 results about "Post immunization" patented technology

The invention provides a novel ecological feed capable of preventing multiple grass-bream diseases, the novel ecological feed comprises a feed matrix and an ecological feed leavening agent, and the ecological feed leavening agent comprises probiotics with surface expression antigens, the antigen is any one or more of a grass carp reovirus antigen, a flavobacterium johnsonii antigen, an aeromonas veronii antigen and a clonorchis sinensis antigen. The novel ecological feed with a disease-resistant function in a parabramis pekinensis breeding mode is prepared for the first time, the resistance of the parabramis pekinensis to various pathogens can be enhanced, and the survival rate of the parabramis pekinensis in the disease attack peak period can be increased by 50% or above after immunization. An oral immunization mode is adopted and can be completed in the feeding process, and the immunization and breeding cost is greatly saved.

The invention discloses a conservative B cell epitope peptide of goose parvovirus VP3 protein, a nucleic acid molecule, a recombinant vector and application thereof. Conservative B cell epitope EW12 is inserted into F18 Escherichia coli Fod fimbriae, inert carrier bacteria S9H are introduced, recombinant bacteria capable of functionally exhibiting and expressing the EW12 conservative B cell epitope on the surface of the bacteria are obtained, the recombinant bacteria can specifically generate specific binding reaction with gosling plague egg yolk antibody and gosling plague vaccine immune serum, and the gosling plague egg yolk antibody and the gosling plague vaccine immune serum can be specifically combined with the gosling plague egg yolk antibody and the gosling plague vaccine immune serum. The method has the advantages that macroscopic agglutination particles are generated, cross agglutination reaction with other pathogen positive serum and healthy goose serum is avoided, the method is good in sensitivity, and the specific antibody can be detected in the 5th day after immunization at the earliest. A plate agglutination test directly mediated by the goose parvovirus VP3 protein conservative B cell epitope peptide EW12 has the advantages of specificity, sensitivity, convenience in operation and suitability for on-site large-scale rapid detection, and is expected to provide a new technical means for diagnosis, prevention and control and purification of GPV infection.

The invention is applicable to the field of genetic engineering, and provides a mycobacterium tuberculosis Mce1A-LS protein nanoparticle, a preparation method and application thereof, the mycobacterium tuberculosis Mce1A-LS protein nanoparticle is formed by sequence fusion of mycobacterium tuberculosis Mce1A protein and LS protein, and the amino acid sequence of the mycobacterium tuberculosis Mce1A-LS protein nanoparticle is shown as SEQ ID NO: 2 in a sequence table. The Mce1A-LS protein nanoparticle provided by the invention is high in immunogenicity, the protein Mce1A with high immunogenicity can induce to generate a synergistic immune effect and is high in safety, and the expressed fusion protein is non-toxic and harmless, so that the biosafety is high, in addition, the immune effect of the Mce1A-LS protein nanoparticle is good, and after the Mce1A-LS protein nanoparticle is used for immunizing a mouse, the immunogenicity of the Mce1A-LS protein nanoparticle is greatly improved. Strong body fluid and / or cellular immune response can be generated, which indicates that after immunization, a specific immune effect can be generated in a mouse body.

The present application relates to the technical field of veterinary biological products, in particular to application of oridonin in preparation of poultry vaccine adjuvant. The poultry vaccine adjuvant is composed of oridonin, solvent and buffer. Experiments prove that after mixing the poultry vaccine adjuvant with poultry inactivated vaccine (such as Newcastle disease vaccine) for immunization, the humoral immune level of poultry can be significantly improved (HI titer of 21d after the second immunization is increased by more than 1.5 log2), and the secretion level of specific IgY (systemic immunity) and IgA (mucosal immunity) in serum can be extremely significantly up-regulated, and the high level of antibody is maintained for more than 4 weeks longer than that of the conventional vaccine group. Compared with commercial adjuvant ISA 201, the present application has better immune enhancement activity, high safety, no adverse reaction at injection site, and wide clinical application prospect.

The application discloses a preparation method of a novel inhalable anthrax component vaccine based on a mutant strain of anthrax bacillus, and relates to the technical field of immunology medicine. The application provides a mutant strain of anthrax bacillus, and a mutant strain A16R-5.1 with six extracellular protease activity related genes deleted. The vaccine is extracted from the culture supernatant of anthrax prepared by using the mutant strain A16R-5.1, and can induce strong humoral, cellular and mucosal immune responses after immunization, can resist the invasion of anthrax spores, and can neutralize anthrax toxin in an in-vitro experiment.

The invention relates to the field of veterinary biological products, in particular to a porcine epidemic diarrhea virus attenuated strain and a vaccine and application thereof. The porcine epidemic diarrhea virus attenuated strain provided by the invention is obtained through in-vitro separation culture and continuous five rounds of plaque purification and screening technology, and has stable culture characteristics. Meanwhile, the virulence of the strain on newborn piglets and weaned piglets is remarkably reduced, and the virulence does not have the phenomenon of reversion after continuous passage for five times in a pig body. The strain has good immunogenicity, and mucosal immunity and systemic immune response of an organism can be activated at the same time by adopting an oral immunization mode. A neutralizing antibody of 1: 8-1: 16 can be detected in oral fluid and serum after the piglets are immunized for 14 days, and a large amount of sIgA is generated in milk after the pregnant sows are immunized, so that the piglets obtain effective passive immune protection.

The invention relates to a recombinant rabies virus. The recombinant rabies virus is obtained by inserting an antigen gene of feline calicivirus and an antigen gene of feline herpes virus into a genome of a rabies virus attenuated strain. The triple inactivated vaccine for preventing and treating the feline calicivirus disease, the feline herpes virus disease and / or the rabies is prepared based on the recombinant rabies virus, and after the triple inactivated vaccine is used for immunizing cats, neutralizing antibodies aiming at the feline calicivirus disease, the feline herpes virus disease and the rabies virus can be effectively induced and generated; the simultaneous immunization on the three viruses is realized.

The application discloses a recombinant pseudorabies virus strain expressing classical swine fever virus E2 protein and application, and relates to the technical field of biology.The recombinant E2 protein provided by the application successfully realizes high-level expression of the E2 protein by removing the transmembrane region of the E2 protein and using the 18aa signal peptide of the E2 protein itself and a pig albumin signal peptide.The recombinant PRV expressing the classical swine fever virus (CSFV) E2 protein can induce E2 antibodies and cellular immunity after immunization of mice.The recombinant pseudorabies virus strain provided by the application can be used as a bivalent vaccine for preventing CSFV and PRV infection.

The invention belongs to the field of biological products and the field of nucleic acid vaccines, and particularly relates to a virus (oropravirus)-like particle, preparation and application of the virus (oropravirus)-like particle as a vaccine. The virus-like particles are Oropers virus-like particles, and the virus-like particles contain proteins encoded by M genome segments of OROV strains or proteins encoded by gene segments of the M genome segments and N proteins of the OROV strains; wherein the corresponding sequence can also be a consistency sequence with the similarity of 75% with the corresponding sequence. Meanwhile, the particle VLP is used as a serum binding antibody of an antigen and an evaluation method of a T cell reaction, and the method can be used for detecting a serum lifting method after vaccine immunization. The invention further provides five nucleic acid vaccines for coding different functional domains of the OROV and combinations thereof, the immunogenicity and T cell reaction induced by the nucleic acid vaccines under different design strategies are displayed, strong body fluid and cell reaction is still kept 154 days after immunization, and it is proved that the nucleic acid vaccines can induce lasting and efficient immune reaction, and the immunogenicity and the T cell reaction are not influenced. The method can be used as a technical reserve and has huge clinical significance and application scenarios.

This application discloses a recombinant hemagglutinin protein, its uses, expression methods, and subunit vaccines, belonging to the field of biomedical technology. The technical solution is as follows: a recombinant hemagglutinin protein, obtained by removing the transmembrane and intracellular regions of the HA protein sequence of the H7N9-235 strain and fusing a T4-foldon sequence at the C-terminus; or by retaining the full-length sequence of the HA protein of the H7N9-235 strain. The amino acid sequence of the recombinant hemagglutinin protein is shown in SEQ ID NO.1 or SEQ ID NO.2. The application also discloses a recombinant hemagglutinin protein with good immunogenicity and medical prospects based on the H7N9 strain. Furthermore, when a subunit vaccine is prepared using the recombinant hemagglutinin protein with the transmembrane and intracellular regions removed, the immunogenicity after secondary immunization is significantly enhanced.

The present invention discloses a rabies inactivated vaccine diluent and its preparation method and application, belonging to the technical field of vaccine diluents. The invention provides an inactivated vaccine diluent to solve the technical problems of low antibody titer, long production time and short antibody maintenance time after animal inactivated vaccine immunization. The invention provides a rabies inactivated vaccine diluent, which is composed of the following components: phosphate buffer, MONTANIDE TM GEL 02 PR adjuvant, canine interferon, and ricin B chain protein. This diluent can significantly increase the rabies neutralizing antibody titer after rabies inactivated vaccine administration.

The invention discloses a method for preparing a sheep-derived positive serum reference of yersinia enterocolitica, obtained positive serum and application of the positive serum, and belongs to the field of veterinary medicine products. The invention aims to solve the technical problem of how to obtain the yersinia enterocolitica sheep-derived positive serum reference which is stable in titer and character and can be used for specific detection of brucella diagnostic products. Therefore, the invention provides a method for preparing the yersinia enterocolitica sheep-derived positive serum reference, which comprises the following steps: immunizing a tested sheep by using an immunizing antigen, and collecting serum of the immunized tested sheep to obtain the yersinia enterocolitica sheep-derived positive serum reference. The immune antigen is an inactivated yersinia enterocolitica obtained by inactivating the yersinia enterocolitica. The positive serum reference can be effectively applied to quality control evaluation work of brucellosis related diagnosis products, and plays a positive role in prevention and control of brucellosis.

The application discloses an egg yolk antibody against Nocardiosis and a preparation method and application thereof, and relates to the technical field of biological medicines. A light chain sequence of the egg yolk antibody comprises a sequence shown in SEQ ID NO. 1, and a heavy chain sequence comprises a sequence shown in SEQ ID NO. 2. The application expands culture of pathogenic bacteria Nocardia, prepares an inactivated bacterin vaccine, and immunizes hens, so that the hens produce egg yolk antibodies against Nocardia through an immune response. After immunization, the application collects eggs, extracts the egg yolk antibodies against Nocardiosis from egg yolk by using a water dilution method. It is verified that the egg yolk antibodies have a strong binding capacity with Nocardia, can effectively inhibit Nocardia, and the titer can reach 1:64000 at the highest.

The invention provides an FcRn-targeted Brucella multi-epitope nano vaccine, which can realize long-term protection, shows continuous immune memory, has high-frequency hair-growing central B cells (GCB), follicular helper T cells (TFH) and central memory T cells (TCM), and ensures long-term immune surveillance; even six months after immunization, the serum IgG titer is still obviously higher than that of a control group; efficient antigen delivery can be achieved, specifically, a chitosan-based nano-particle system is adopted, and antigen protection and intestinal epithelium uptake are enhanced through FcRn targeted ligand modification; the delivery efficiency can be improved by 10 times, and the gastrointestinal mucosal barrier is overcome; in addition, rapid immune starting can be achieved, multi-dimensional immune response is induced within 14 days after final immunization, and rapid protection is provided for resisting brucella infection.

The application belongs to the technical field of molecular biology, and particularly relates to an anti-CD28 nanobody and a preparation method and application thereof. The anti-CD28 nanobody provided by the application is prepared in the following manner: constructing a CD28 antigen to immunize a llama, constructing a phage library to the PBMC of the immunized llama, screening the phage library, selecting correct sequences to construct and express and purify, and finally obtaining the anti-CD28 nanobody through cell function detection screening. The nanobody provided by the application has specific recognition and binding capacity for CD28, has the advantages of high specificity, high sensitivity and the like, effectively reduces the development and production cost of the CD28 antibody, and shortens the expression time of the antibody.

To provide vaccines and methods.SOLUTION: Described herein are methods for identifying optimized antigenic pathogen polypeptides capable of inducing a broadly neutralizing immune response and associated T-cell responses to a pathogen, and nucleic acid sequences encoding such polypeptides. Also described are methods for determining whether a broadly neutralizing immune response is induced in a subject following immunization with an optimized antigenic pathogen polypeptide or a nucleic acid encoding the optimized pathogen polypeptide. Further described are nucleic acid molecules, polypeptides, vectors, cells, fusion proteins, pharmaceutical compositions, and their use as vaccines against pathogens, especially against emerging or re-emerging pathogens (particularly RNA viruses).SELECTED DRAWING: None

The purpose of the present invention is to provide, as a platform technique that may serve as preparation for pandemics, a rapid antibody production technique in which a non-human animal having a human antibody gene is used. More specifically, the purpose of the present invention is to provide an immunization method with which it is possible to induce, in a short period of time, a high antigen-binding ability of an antibody or a high antibody titer of an antiserum, and a method for producing a human antibody / antiserum with which it is possible to rapidly produce a wide range of neutralizing antibodies.　(1) An immunization method for rapidly inducing a human monoclonal antibody having a high ability to bind to a desired antigen or a human polyclonal antibody having a high antibody titer, the method comprising a step for immunizing a non-human animal a plurality of times with a desired antigen or a nucleic acid encoding the antigen within 30 days from the first immunization, the non-human animal having a human antibody gene or locus, and the non-human animal being such that an endogenous gene or locus of the non-human animal corresponding to the human antibody gene or locus is disrupted or deleted, or mutated so as to result in a loss of expression or low expression. (2) A method for producing a human antibody against a desired antigen using a non-human animal, the method comprising: an immunization step for immunizing the non-human animal with the antigen or a nucleic acid encoding the antigen; a human immunoglobulin-positive B cell isolation step for isolating B cells that are human immunoglobulin-positive from a tissue of the immunized non-human animal; an antibody base sequence acquisition step for acquiring the base sequences of antibody light-chain mRNA-derived cDNA and antibody heavy-chain mRNA-derived cDNA prepared from the isolated B cells; and an antibody production step for producing an antibody on the basis of the acquired antibody base sequence, the non-h

The application discloses a novel group B meningococcal outer membrane protein bifunctional carrier, relates to the technical field of biopharmaceutical processes, and discloses a group B meningococcal outer membrane protein bifunctional carrier and application of the bifunctional carrier in a meningitis combined vaccine. The bifunctional carrier is human H factor binding protein fHbp, and comprises two kinds of recombinant proteins BA and BB, and the amino acid sequences of the two kinds of recombinin proteins are SEQ ID No. 62 and SEQ ID No. 63 respectively. The BA protein is coupled with group A capsule polysaccharide to form a group A combined vaccine, the BB protein is coupled with group C capsule polysaccharide to form a group C combined vaccine, and the two are mixed to form a group ABC triple vaccine. Each dose of the triple vaccine contains 40 μg of group A / C polysaccharide, 160 μg of BA / BB protein in total and 1.0 mg of aluminum adjuvant. The BA and BB proteins are expressed by E. coli, are broken by high-pressure homogenization, and are purified by anion exchange chromatography, and the purity is greater than or equal to 95%. The triple vaccine can simultaneously induce immune responses to groups A, B and C of meningitis, the serum bactericidal titer is greater than or equal to 1:32 after primary immunization, and the titer is maintained for more than 56 days after three immunizations.

The invention relates to the technical field of tuberculosis vaccines, in particular to a tuberculosis VLP nanoparticle vaccine and preparation and application thereof. According to the tuberculosis VLP nanoparticle vaccine, through up-regulation of Th1 type, Th2 type and TH17 type cellular immune response and down-regulation of Treg cellular immune response, the H37Rv growth inhibition ability of splenic lymphocytes and lung cells in vitro is enhanced, and the cellular immune response induced by EPPE + mi3 / AS01E and the H37Rv growth inhibition ability of the cells in vitro are higher than those of BCG and a corresponding subunit vaccine EPPE / AS01E; in addition, the EPPE + mi3 / AS01E can be used as a BCG booster vaccine, and the cell immune response after BCG immunization and the H37Rv growth inhibition capacity of cells in vitro are improved.

The invention discloses a breeding informatization management system based on intelligent agriculture big data, and relates to the technical field of big data management, and the system comprises a breeding file establishment module which is used for taking the specific immune response intensity and stability of a target pathogen as core breeding indexes, screening excellent parents to construct a basic breeding group, and establishing a breeding file; establishing a breeding file containing pedigree, genotype and immune related molecular markers; the immune archive binding module is used for creating a structured immune archive for the individual based on the archive and binding a unique identifier; the immune program formulating module is used for formulating differentiated immune programs according to genetic background layering; the immune program optimization module is used for scanning an identifier at an immune spot to automatically match an optimization scheme; and the multi-index combined seed selection module is used for quantifying the post-immune titer index into a new breeding character and feeding the new breeding character back to the breeding system, so that closed-loop optimization is realized. According to the method, the breeding efficiency, the immune precision and the group disease resistance can be remarkably improved.

The invention discloses a method for improving the expression quantity and immunogenicity of a novel plant-derived coronavirus RBD-sc-dimer, and claims to protect a recombinant plasmid, and the recombinant plasmid comprises an optimized target protein sequence. The optimized target protein sequence sequentially comprises a gene sequence of a signal peptide as shown in a sequence 2, a gene sequence of a target protein dimer and a nucleotide sequence as shown in a sequence 8 from the 5'end to the 3 'end; the optimized target protein sequence is positioned behind the 35S promoter in the plasmid. According to the plant source protein prepared through the recombinant plasmid, RBD-sc-dimer is fused with 10 serine-proline dipeptides, and secretory expression is achieved through an SSExt signal peptide. Experimental results show that by means of the design, the expression quantity of RBD-sc-dimer can be increased by 2.4 times, and the total IgG level after three times of immunization of 10 g of recombinant protein is increased by about 100 times.

The invention relates to the technical field of drug delivery and tumor immunotherapy, and discloses nested lipid nanoparticles for immunotherapy synergy as well as a preparation method and application of the nested lipid nanoparticles. The nLNP has a double-layer nested structure with an inner layer carrying Hsc70 mRNA and an outer layer carrying an STING agonist MSA-2 prodrug, and an inner layer nitrogen stacking group and an outer layer DBCO group are connected through a click reaction to realize tumor pre-targeting enrichment; the pH response lipid on the outer layer is dissociated preferentially in a slightly acidic environment, firstly releases an MSA-2 prodrug to activate innate immunity, and then releases Hsc70 mRNA to reverse PD-L1 related drug resistance, so that the curative effect of the immune checkpoint inhibitor is synergistically enhanced. The preparation provided by the invention has the advantages of strong targeting property, controllable release and good safety, and is suitable for drugs or pharmaceutical compositions for tumor immunotherapy synergy.

This invention discloses the construction of a Toxoplasma gondii progesterone-responsive kinase-deficient strain and its application as a live attenuated vaccine. The Toxoplasma gondii progesterone-responsive kinase-deficient strain is derived from Toxoplasma gondii RHΔ... ku80 As a maternal strain, the gene-editing technology was used to knock out the enzyme encoding progesterone-responsive kinase. prk The gene-deleted strain was named RHΔ ku80 Δ prk Experiments have shown that RHΔ ku80 Δ prk The virulence of the strain was significantly reduced, and immunized mice showed good immunoprotection against acute infection with highly virulent and moderately virulent Toxoplasma gondii strains, and significantly inhibited brain cyst formation in a chronic infection model. Therefore, RHΔ ku80 Δ prk This invention has potential application value as a live attenuated vaccine against Toxoplasma gondii. It has significant application prospects.

The application belongs to the technical field of biology and relates to an RSV pre-F mutant, a preparation method and application thereof. Compared with a wild-type F0 polypeptide, the RSV pre-F mutant satisfies the following conditions: (1) does not contain a furin enzyme cutting site fragment, a P27 polypeptide, a transmembrane domain and an intracellular domain; (2) has mutations S180C, S186C, A170C, V179C, A241C, Q279C, D486C and A490C; and (3) the C terminal of an F1 polypeptide is not connected or connected with an aggregation motif. The mutant and a trimeric conformation thereof are both highly stable, can self-assemble into a trimer without a heterologous trimeric domain, can induce high levels of binding antibodies and neutralizing antibodies after immunization, avoid high levels of non-neutralizing active binding antibodies produced when immunization is performed on the heterologous trimeric domain, and thus improve the quality of antibodies.

The application provides a hybridoma cell strain secreting a monoclonal antibody against a alginate mannuronic acid tetrasaccharide epitope, a monoclonal antibody and application. In order to enhance the immunogenicity of the mannuronic acid tetrasaccharide, a glycoconjugate KLH-1 is used as an immunogen to inject and immunize a mouse, so that the mouse is stimulated to produce a specific immune response against the mannuronic acid tetrasaccharide epitope, then spleen cells of the immunized mouse are fused with myeloma cells, and after screening, an initial hybridoma cell strain is obtained; then after subcloning and specific screening, a hybridoma cell strain capable of stably secreting a monoclonal antibody of the target mannuronic acid tetrasaccharide epitope in alginate is obtained, and a monoclonal ascites antibody is further obtained. The monoclonal ascites antibody shows specific recognition and combination ability for pseudomonas aeruginosa, and the combination activity is related to the expression level of alginate on the surface of the bacteria. Therefore, the monoclonal ascites antibody can be used as a precise detection and diagnosis tool for pseudomonas aeruginosa, and can also be applied to the antibacterial treatment of pseudomonas aeruginosa infection.

The present application relates to the field of immunoassay technology, and provides a myclobutanil hapten, antigen, antibody and preparation method and application. The present application introduces an active group at the meta position of the chlorine atom on the benzene ring of myclobutanil. Compared with the existing hapten, the hapten provided by the present application completely simulates the structure of myclobutanil, and enhances the immunogenicity of the antigen. The antigen provided by the present application has strong immunogenicity after being coupled with a carrier protein. After injection immunization of mice, the titer of the produced antibody is 5.0x10 4 , the half-inhibitory concentration (IC 50 ) is about 50 ppb, and the minimum detection limit of colloidal gold for myclobutanil in dry tobacco leaf samples is about 2.5 μg / g.

The invention relates to the technical field of immunoassay, and provides a vomitoxin hapten, an antigen, an antibody, a preparation method and a light-activated chemiluminescence quantitative detection kit. The hapten is obtained by adopting cyclic dicarboxylic anhydride as a reactant and introducing an active group on a C atom of conjugated alkene of vomitoxin molecules through Friedel-Crafts acylation reaction. After the hapten is coupled with a carrier protein, vomitoxin molecules can be fully exposed outside the carrier protein, the immunogenicity of the antigen is enhanced, and an antibody with high titer and high sensitivity can be generated after the hapten is immunized by a host animal. Results of the embodiment show that after the vomitoxin antigen is subjected to mouse injection immunization, the titer of the generated antibody is 1: 20000, and the half inhibitory concentration (IC50) is less than 50ppb / mL. When the obtained vomitoxin antigen and antibody are applied to rapid quantitative detection of light-activated chemiluminescence of vomitoxin, the detection limit, the false negative rate and other dimensions are qualified, the detection steps are simple, and the vomitoxin antigen and antibody have good industrial value.

The application discloses a chimeric Kunjin virus of tamabi virus prM-E and a preparation method and application thereof. On the basis of a reverse genetic manipulation system of the Kunjin virus KUNV, the KUNV prM / E gene is replaced by the DTMUV prM / E gene to construct a chimeric DTMUV virus infectious clone plasmid with the KUNV as a skeleton, which is named as pUC19-KUNV-DTMUV prM / E. Then, the chimeric tamabi virus prM-E Kunjin virus is obtained through virus rescue, and is named as rKUNV-CHv-prM / E (CHv). Analysis on the virus characteristics shows that the CHv can effectively proliferate in BHK-21 and DEF cells, and the duck embryo virulence is weaker than that of the KUNV and the DTMUV. The animal experiment results show that the CHv only detects obvious virus levels in the brain, and does not produce viremia; the CHv after immunization can produce similar IgG antibody levels to those after immunization of the KUNV and the DTMUV. Therefore, the recombinant virus of the chimeric DTMUV prM / E with the KUNV as a skeleton prepared by the application can induce the duckling to produce sufficient immune protective neutralizing antibody levels, and can be applied to preparation of a duck tamabi virus vaccine.

The application provides a kind of construction and application of PRRSV live vector vaccine strain of recombination expression PEDV S protein receptor RBD domain, and the results show that the dominant antigen region of PEDV S protein RBD function domain can be expressed in the recombination virus rHuN4-F112-SRBD1 rescued, and the biological characteristics of recombination virus are similar to parent virus.The nucleotide sequence of SRBD1 gene introduced in each generation of recombination virus and the amino acid sequence encoded thereby are not deleted or mutated, and the IFA and Western Blot detection results show that the SRBD1 gene introduced in different generations of recombination virus rHuN4-F112-SRBD1 can be stably expressed, and does not affect the expression of parent virus itself protein, indicating that the recombination virus rHuN4-F112-SRBD1 strain has genetic stability.The immunogenicity analysis of recombination virus rHuN4-F112-SRBD1 shows that the recombination virus rHuN4-F112-SRBD1 strain can induce specific antibodies against PEDV S protein and PRRSV2 in piglets after immunization, and the antibodies induced have neutralizing effect on PEDV epidemic strain, and can be used for the development and development of PRRS and PED novel genetic engineering vaccine.

The application belongs to the field of marine biotechnology, and particularly relates to natural polysaccharide-quaternized chitosan nanoparticles with immune stimulation and preparation and application thereof. The nanoparticles formed by natural polysaccharide with negative charge and quaternized chitosan with positive charge are obtained by polyelectrolyte complexation, the particle size is 316.4 nm, and the potential is 31.1 mV; the quaternized chitosan with positive charge and the natural polysaccharide with negative charge are mixed in a mass ratio of 6.25-10:1-4. After immunization of mice, the secretion amount of immunoglobulin IgG and immune factors in the mice is determined, which shows that the nanoparticles have good immune activity, thereby playing an effect in vaccine adjuvant. The application provides a method and guidance for the research on natural polysaccharide and chitosan derivatives as immune adjuvants in recent years.